Lynwood Capital Management Inc. Cingulate Inc. Call Options Transaction History

Lynwood Capital Management Inc.

  • $11.2 Million
  • Q1 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About Cingulate Inc.

CING Quotes by TradingView
  • Ticker CING
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,309,400
  • Market Cap $42.2M
  • Description
  • Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-de...
More about CING
Track This Portfolio

Track Lynwood Capital Management Inc. Portfolio

Follow Lynwood Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynwood Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Lynwood Capital Management Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email